PD-L1 t-haNK

PD-L1 t-haNK is a novel immuno-oncology therapy based on engineered natural killer (NK) cells derived from the NK-92 cell line. These cells are genetically modified to express a chimeric antigen receptor (CAR) targeting programmed death-ligand 1 (PD-L1), along with high-affinity CD16 receptor and endoplasmic reticulum-retained interleukin-2 (IL-2). This design enables the NK cells to selectively recognize and kill PD-L1-expressing tumor cells through direct cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC). The therapy aims to overcome tumor immune evasion by targeting tumors that upregulate PD-L1 as a mechanism of resistance to T cell-based immunotherapies. Preclinical studies have demonstrated efficacy against multiple solid tumors including triple negative breast cancer, lung cancer, bladder cancer, gastric cancer, glioblastoma, pancreatic cancer and squamous cell carcinoma. Clinical development is ongoing with phase II trials in several solid tumors. The drug was developed by NantKwest and is currently developed by ImmunityBio.

Other names

PD-L1 targeted high-affinity natural killer cellsPD-L-1 targeted high-affinity natural killer cellsPD-L 1 targeted high-affinity natural killer cellst‑haNK